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Abstract Release of membrane vesicles, a process con-
served in both prokaryotes and eukaryotes, represents an
evolutionary link, and suggests essential functions of a
dynamic extracellular vesicular compartment (including
exosomes, microparticles or microvesicles and apoptotic
bodies). Compelling evidence supports the signiﬁcance of
this compartment in a broad range of physiological and
pathological processes. However, classiﬁcation of mem-
brane vesicles, protocols of their isolation and detection,
molecular details of vesicular release, clearance and bio-
logical functions are still under intense investigation. Here,
we give a comprehensive overview of extracellular vesi-
cles. After discussing the technical pitfalls and potential
artifacts of the rapidly emerging ﬁeld, we compare
results from meta-analyses of published proteomic studies
on membrane vesicles. We also summarize clinical
implications of membrane vesicles. Lessons from this
compartment challenge current paradigms concerning the
mechanisms of intercellular communication and immune
regulation. Furthermore, its clinical implementation may
open new perspectives in translational medicine both in
diagnostics and therapy.
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Introduction
The extracellular space of multicellular organisms contains
solutions of metabolites, ions, proteins and polysaccha-
rides. However, it is clear that this extracellular
environment also contains a large number of mobile
membrane-limited vesicles for which we suggest the term
‘‘extracellular vesicles’’ (EVs). EVs include exosomes,
activation- or apoptosis-induced microvesicles (MVs)/mi-
croparticles and apoptotic bodies (Fig. 1). In conventional
histological sections, recognition of the secreted membrane
vesicles is substantially limited by the resolving power of
the light microscope, as their diameter usually falls below
the limit of resolution. Furthermore, not only histological
assessment but also conventional cell biology techniques
including laser confocal microscopy or ﬂow cytometry
(FC) have substantial limitations when used for analysis of
EVs [1]. Thus, it was not until recently that emerging
evidence started to support the notion that vesicle release
may be a universal adaptive cellular response (Fig. 2)
[2–4].
Although initially met with skepticism, the existence of
secreted membrane vesicles is now well established, and
their diverse biological functions have been documented
extensively. Current research interest in the ﬁeld focuses
primarily on two major types of EVs (exosomes and MVs),
whose release may represent a universal and evolutionarily
conservedprocess. Ofnote,EVsalsoinclude othervesicular
structuressuchaslargeapoptoticbodiesaswellasexosome-
like vesicles and membrane particles [2]. Exosome-like
vesicles have common origin with exosomes; however, they
lack lipid raft microdomains, and their size and sedimenta-
tion properties distinguish them from exosomes [2, 5].
Membrane particles are 50–80 nm in diameter, and they
originate from the plasma membrane [6]. Extracellular
membraneous structures also include linear or folded
membrane fragments (e.g., from necrotic death) as well as
membranousstructuresfromothercellularsourcesincluding
secreted lysosomes [7] and nanotubes [8].
In fact, in the extracellular environment of tissues, dif-
ferent types of vesicles are present simultaneously.
Therefore, instead of focusing on a single type of vesicle,
in this review article we summarize data on membrane
vesicles collectively, from a systems biology perspective.
Without claiming completeness, we discuss recent devel-
opments and some burning questions in the ﬁeld.
As a step towards standardization of the terminology, we
use the terms suggested recently by The ´ry et al. [2]. The
only exception is that we use the collective term ‘‘extra-
cellular vesicle’’ (EV) as a synonym of ‘‘membrane
vesicle’’ (the designation that has been suggested for all
populations of cell-derived vesicles). The phrase ‘‘exo-
some’’ refers to vesicles of 50–100 nm in diameter,
Fig. 1 Schematic representation of the extracellular vesicles. Major
populations include exosomes, microvesicles and apoptotic bodies.
To simplify the Figure, cells are not shown to release all types of
vesicles
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123generated by exocytosis of multivesicular bodies (MVBs).
Of note, biological literature also uses the term ‘‘exosome’’
for a macromolecular complex involved in RNA degrada-
tion, while the word ‘‘ectosome’’ (used by some authors to
indicate neutrophil or monocyte derived MVs [9]), also
refers to the outer, cortical layer of sponges [10].
‘‘Microparticle’’ is a general designation used for any small
particles within a given size range irrespective of origin.
Even in biomedical literature the term ‘‘microparticle’’ is
commonly used in the case of biopolymer particles (used as
drug delivery systems), or dietary microparticles (food
additives, pharmaceutical or toothpaste microparticles)
[11], to mention just a few examples of the redundant
terminology. Given that the word ‘‘particle’’ suggests a
solid, particulate structure rather than a vesicular one, the
designation ‘‘microvesicle’’ appears more appropriate to
indicate membrane-limited structures. However, over the
past decades, most studies traditionally referred to these
structures as ‘‘microparticles’’ [e.g. endothelial cell- and
platelet derived MVs were designated as endothelial
microparticles (EMPs) and platelet microparticles (PMPs),
respectively]. Of note, the term ‘‘microvesicle’’ has also
been used by several authors collectively for vesicular
structures released by cells instead of ‘‘membrane
vesicles’’.
To make the terminology unambiguous in this review,
we will use the term ‘‘microvesicle’’ for the larger extra-
cellular membrane vesicles (100–1,000 nm in diameter),
and we will not use the term ‘‘microparticle’’ [2]. The
abbreviation ‘‘MV’’ denotes ‘‘microvesicle’’ and not
‘‘membrane vesicle’’.
Release of membrane vesicles: trogocytosis
From a cell biology perspective, vesiculation may be
classiﬁed as a type of trogocytosis. The transfer of mem-
brane components between donor and acceptor cells was
ﬁrst demonstrated in 1973 [12]. The phenomenon has been
coined ‘‘trogocytosis’’ (from Greek ‘‘trogo’’, meaning
‘‘gnaw’’ or ‘‘bite’’). Some authors suggest that trogocytosis
challenges classical theories of cell autonomy [13], as cells
may receive membrane and cytoplasmic fragments from
other cells. Two forms of membrane transfer (trogocytosis)
have been described: via nanotubes or via membrane ves-
icles [8]. This review focuses on membrane vesicles of the
extracellular environment.
The biogenesis of membrane vesicles essentially dis-
tinguishes exosomes from MVs and apoptotic bodies.
In the following section, we provide a concise overview
of hallmarks of paramount membrane vesicle populations:
exosomes, MVs and apoptotic bodies.
Key features of major vesicle populations
Key features of exosomes
• Exosomes were ﬁrst described by Trams et al. [14]a s
exfoliated vesicles with ectoenzyme activity. This work
was followed by the results of Harding and Stahl
describing release of small vesicles and tubules from rat
reticulocytes [15], and an electron microscopic study
describing the exocytosis of the approximately 50-nm
bodies [16]
• They are vesicles surrounded by a phospholipid bilayer
(approximately 50–100 nm in diameter), their size
range roughly overlaps that of the viruses (Fig. 3)
• They are released both constitutively and upon
induction [2] by exocytosis of multivesicular bodies
(MVBs), important intermediates in endolysosomal
transport formed by the invagination and scission of
buds from the endosomal limiting membrane into the
lumen [17]
• Exosomes have been predominantly characterized in
the case of immune cells (dendritic cells, T cell, B cells,
macrophages) and tumors
• Key mechanisms by which exosomes may exert their
biological functions on cells include (1) direct contact
between surface molecules of vesicles and cells, (2)
endocytosis of vesicles, and (3) vesicle-cell membrane
fusion [2]. Exosomes may horizontally transfer mRNA
and miRNA [18]. Horizontal transfer of oncogenic
receptor [19] and transfer of HIV particles [20] have
been demonstrated in the case of exosomes.
Fig. 2 Summary of some adaptive cellular responses including the
newly recognized vesiculation process. Of note, apoptosis itself
involves vesicle release (shedding of apoptotic microvesicles and
apoptotic bodies)
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123• Examples for key functions of exosomes include
antigen presentation [2, 21] and immunostimulatory
and inhibitory activities [2].
• They feature phosphatidylserine on the outer membrane
leaﬂet [22], and markers include CD63, CD81, CD9,
LAMP1 and TSG101 [23, 24]
• Isolation and analytical methods include differential
centrifugation and subsequent sucrose gradient ultra-
centrifugation [25], transmission electron microscopy
(TEM), western blot and mass spectroscopy
• Basic features of exosomes have been recently covered
by numerous review articles [2, 22, 23, 26–35]
(Table 1)
Key features of microvesicles (MVs)
• MVs were ﬁrst described by Chargaff and West in 1946
as a precipitable factor in platelet free plasma with the
potential to generate thrombin [36]. In 1967, Peter Wolf
Fig. 3 Size ranges of major
types of membrane vesicles.
While exosomes share size
distribution with viruses,
microvesicles overlap in size
with bacteria and protein
aggregates (e.g. immune
complexes). Both apoptotic
bodies and platelets fall into the
size range of 1–5 lm
Table 1 Key features of membrane vesicle populations
Exosomes Microvesicles Apoptotic bodies
Size range Approximately 50–100 nm 100–1,000 nm (*100–400 nm in
blood plasma) [2, 22, 38]
1–5 lm[ 61]
Mechanism of generation By exocytosis of MVBs By budding/blebbing of the plasma
membrane
By release from blebs of cells
undergoing apoptosis
Isolation Differential centrifugation and sucrose
gradient ultracentrifugation [25],
100,000–200,000g, vesicle
density is 1.13–1.19 g/mL
Differential centrifugation [39]
18,000–20,000g
Established protocols are
essentially lacking; most
studies use co-culture with
apoptotic cells instead
of isolating apoptotic bodies
Detection TEM, western blotting, mass
spectrometry, ﬂow
cytometry (bead coupled)
Flow cytometry, capture based
assays [38, 52]
Flow cytometry
Best characterized cellular
sources
Immune cells and tumors Platelets, red blood cells and
endothelial cells
Cell lines
Markers Annexin V binding, CD63, CD81, CD9,
LAMP1 and TSG101 [23, 24]
Annexin V binding, tissue factor
and cell-speciﬁc markers
Annexin V binding, DNA content
Recent review articles [2, 22, 23, 26–35][ 2, 24, 35, 53–57]
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123described ‘‘platelet dust’’, a fraction containing mainly
lipid-rich particles separated by ultracentrifugation
from fresh plasma [37]
• MVs are structures surrounded by a phospholipid
bilayer. They are 100–1,000 nm in diameter [2]o r
*100–400 nm in blood plasma [38], but the lower cut-
off remains to be established [39]. Their size range
overlaps that of bacteria and insoluble immune com-
plexes [38] (Fig. 3)
• They are formed by regulated release by budding/
blebbing of the plasma membrane.
• The rate of steady state release of budding/shedding
vesicles [35] is generally low (except for tumors that
release them constitutively [40]).
• Regulated release of vesicles is efﬁciently induced upon
activation of cell surface receptors or apoptosis and the
subsequent increase of intracellular Ca
2? [41, 42]
• They have been predominantly characterized as prod-
ucts of platelets, red blood cells and endothelial cells.
• Examples of key functions of MVs: they have procoag-
ulant activity [43], represent a form of secretion of IL1b
[44], contribution to the pathogenesis of rheumatoid
arthritis [45–47], contribution to the proinvasive char-
acter of tumors [48], induction of oncogenic cellular
transformation [49], fetomaternal communication [50]
• They feature phosphatidylserine; however, some obser-
vations also suggest the existence of MVs without
phosphatidylserine externalization [51]
• Routine isolation and analytical methods include dif-
ferential centrifugation [39], ﬂow cytometry (FC) and
capture-based assays [38, 52]
• Basic characteristics, molecular and functional aspects
have been summarized by several recent review articles
[2, 24, 35, 53–57]
Key features of apoptotic bodies
• The term ‘‘apoptotic body’’ was coined by Kerr in 1972
[58], and the next milestone work in apoptosis research
was conducted by Robert Horvitz et al. tracing cell
lineage development in the nematode Caenorhabditis
elegans [59, 60]
• Apoptotic bodies are 1–5 lm in diameter (approxi-
mately the size range of platelets) [61]
• Apoptotic bodies are released as blebs of cells under-
going apoptosis
• They are characterized by phosphatidylserine external-
ization, and may contain fragmented DNA [62]
• Examples of key functions of apoptotic bodies are
horizontal transfer of oncogenes [63], horizontal transfer
ofDNA[64],yieldingpresentationofTcellepitopesupon
uptake by phagocytic cells [65] and representation of B
cell autoantigens [66]. Uptake of apoptotic bodies has
been shown to lead to immunosuppression [67].
• Instead of isolating apoptotic bodies, most studies use
co-cultures of cells undergoing apoptosis to investigate
the functions of these structures.
In spite of extensive research, the rapidly emerging ﬁeld of
membrane vesicle research remains technically difﬁcult. In
the next section, we aim to overview major challenges and
recent methodological improvements.
Problems and pitfalls associated with membrane vesicle
measurement
In this section, we aim to summarize the difﬁculties associ-
atedwithisolationofmembranevesiclesandstandardization
of pre-analytical and analytical factors of membrane vesicle
assessments.
Isolation of membrane vesicles
There is a widely accepted protocol for exosome isolation,
which includes ultracentrifugation and a subsequent sucrose
densitygradientultracentrifugationor,alternatively,sucrose
cushion centrifugation [25]. In contrast, standard isolation
protocols for MVs are lacking. Most groups apply centrifu-
gation conditions from 18,000g (30 min) to 100,000g
(60 min) [68]. Standard isolation protocols for apoptotic
bodiesareabsentintheliterature.Inbiologicalﬂuidsandcell
supernatants, the previously described membrane vesicle
populations are present simultaneously with possible size
overlap.Whileimmuneafﬁnityisolatedexosomeshavebeen
shown to have a diameter\100 nm [69], it has not yet been
convincingly demonstrated that all MVs are larger than the
100-nm limit. Moreover, the statement that MVs may not be
\100 nm should be made with some caution. Booth et al.
have shown vesicles of this size (and even smaller) budding
from the plasma membrane [70].
A further substantial problem is that during differential
centrifugation prior to pelleting of a given membrane vesicle
population,someoftherespectivevesiclesmaybeselectively
depleted. For example, centrifugation of cells or platelets
results in a substantial loss of MVs [71]. To analyze blood-
derived MVs, platelet-free plasma is required. However,
currently there is no consensus on the centrifugation times,
forcesorthenumberofcyclesfortheremovalofplatelets.For
completeremovalofplatelets,an800-nmﬁltrationisrequired
after centrifugation [38]. Of note, forced ﬁltration of mem-
brane vesicles holds the risk of fragmentation into smaller
vesicles [72]. To avoid this problem, we recommend gravity-
driven ﬁltration [38].
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differential centrifugation is complicated by the possibly
overlapping size distributions of platelets and different
membrane vesicle populations. Furthermore, centrifugation
alone may prove insufﬁcient to separate vesicles based on
their sizes. However, differential centrifugation, when
combined with sucrose gradient ultracentrifugation, can
separate exosomes from MVs. A further alternative method
to differential centrifugation, immunoisolation of mem-
brane vesicles, may overcome these limitations [25, 69].
Size determination of different membrane vesicle
populations
Despite the existence of several methods available to
determine the size of vesicles, the precise determination of
the size distribution of a given vesicle preparation seems to
be unexpectedly difﬁcult. FC is a convenient technique;
however, it has severe limitations in resolving structures
below 200 nm [22]. The gold standard for vesicle size
determination remains transmission electron microscopy
(TEM) [1]. For TEM studies, vesicles need to be concen-
trated by centrifugation. However, there are some concerns
about the reliability of analysis of pelleted vesicles: cen-
trifugation, dehydration and ﬁxaton for TEM may alter the
size and morphology of vesicles. Newer techniques (such
as cryo-EM) led to the ﬁnding that the ‘‘cup-shaped’’
morphology of exosomes was an artifact related to ﬁxation
for TEM [25]. Despite these concerns, TEM is the only
method by which the nature of the particle, its size and
structure may be determined at the same time. Surface-
bound particles are studied by atomic force microscopy
(AFM). AFM has some limitations in analyzing non-rigid
particles: the z value (the height of the particle) seems to be
much smaller than the x, y values (characteristic for the
surface area) [73]. Yuana et al. hypothesized that the ves-
icle volume is constant; therefore, the diameter of surface-
bound vesicles is much smaller than the x, y values, if we
consider the low z value. However, the low z value may
also result from the tapping mode analysis of the AFM (the
up- and downward motion of the AFM tip may cause
deformation of vesicles) or from the drying step. This is
supported by our AFM data showing concordant results
with TEM and dynamic light scattering analysis without a
correction for the z value [38].
Dynamic light scattering analysis (DLS) is a useful
method for membrane vesicle sizing; however, it has lim-
itations, particularly when the analyzed system is
polydisperse. Our work based on TEM, AFM and DLS
analysis, supported by the work of others [72], suggested
that the blood plasma-derived MVs, isolated by
20,500g centrifugation, were 100–400 nm in diameter
(mean = 170 nm) [38]. Nanoparticle tracking analysis is
an alternative method to DLS and, particularly in the
ﬂuorescent mode, it is capable of analyzing highly poly-
disperse structures between 50 and 1,000 nm [1]. Results
obtained with this method are highly concordant with the
TEM measurements [1]. Other methods for vesicle size
determination such as stimulated emission depletion
microscopy or ﬂuorescence correlation spectroscopy have
been recently reviewed by van der Pol et al. [1].
Pre-analytical challenges
There are growing concerns about pre-analytical variables,
particularly in the ﬁeld of the diagnostic use of MVs.
These pre-analytical factors were addressed insufﬁciently
by earlier works in the literature. However, there are data
regarding the alterations of the MV count in erythrocyte
concentrates and platelet-rich plasma. It has been shown
that platelets vesiculate in response to shear stress [74] and
storage [75] (Fig. 4). In the study of Connor et al., it has
been shown that freeze–thaw cycles of platelet-rich plasma
resulted in a substantial increase of annexin V
? MV count
[51]. In erythrocyte concentrates, the MV count varies with
storage time, temperature, the buffer used to dilute MVs,
and, most interestingly, with agitation [71]. Rubin et al.
have shown that vortexing the erythrocyte concentrates for
20 s doubled the MV count [71]. These data strongly
suggest that cells, particularly platelets and erythrocytes,
are highly sensitive to environmental factors and respond
by release of MVs (Fig. 4), which may lead to confound-
ing results. As a consequence, during the assessment of
Fig. 4 Transmission electron micrograph of a platelet from normal
human blood plasma releasing membrane vesicles (pMVs). Original
magniﬁcation 930,000
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venipuncture to sample analysis must be standardized
precisely. These steps include (1) the diameter of the
needle used for venipuncture, (2) duration of placement of
the tourniquet, (3) the type of anticoagulants used, (4)
centrifugal speed to yield platelet-free plasma, (5) working
and storage temperature of the sample, (6) freeze–thaw
cycles, (7) needle-to-analysis time, and (8) analysis pro-
tocols [39, 76]. It is critical that cells and platelets from
biological ﬂuids be pelleted shortly after collection (pref-
erably within an hour), and before frozen stage. In order to
minimize the effect of pre-analytical variables, recently, a
workgroup has launched a joint project on standardization
of MV analysis (International Society on Thrombosis and
Haemostasis, Scientiﬁc and Standardization Committee:
Standardization of Pre-analytical Variables in Plasma
Microparticle Determination). The preferred protocol
includes collection of blood samples in citrate containing
tubes. In order to deplete blood samples in platelets, cen-
trifugation twice with 2,500g for 15 min is recommended
(F. Dignat-George, personal communication). After snap-
freezing in liquid nitrogen, the samples should be stored at
-80 C.
On the other hand, there are only limited data on pre-
analytical variables in the case of exosomes. Some pre-
analytical challenges have been demonstrated with respect
to urinary exosomes as new biomarkers of kidney disease.
During the pre-centrifugation step, urinary exosomes may
become entrapped in the polymeric Tamm–Horsfall protein
leading to a loss of exosomes [77]. Furthermore, possible
viral contamination with the common presence of several
hosts molecules, e.g., MHC-II molecules in both virions
and exosomes, also need to be considered during exosome
detection. Optiprep velocity gradients have been recently
suggested to efﬁciently separate exosomes from HIV-1
particles [78].
Flow cytometric detection of membrane vesicles
As described above, standard FC detects vesicles above
approximately *200 nm, and therefore exosomes and
smaller MVs cannot be analyzed directly by this method.
Thus, it has to be emphasized that MVs smaller than the
detection limit of the used ﬂow cytometer cannot be dis-
criminatedfromtheinstrumentnoise,leadingtoaninadequate
numberingofMVs(becauseofnotdetectingthevastmajority
of vesicles that are present in the sample). Despite these lim-
itations, FC is a widely used method for MV detection, and
using FC, many studies have reported that MV counts corre-
lated with a variety of diseases and different physiological
conditions.Recently,there havebeenmajorimprovementsin
the standardization of FC measurements of membrane vesi-
cles [79, 80]. This is a prerequisite for the diagnostic and
prognostic use of MV measurements. FC platforms for small
size EV analysis are being developed by BD, Beckmann
Coulter, Apogee; however, these are not yet widely available
(except for the Apogee system).
In many of the earlier FC studies, annexin V was used as
a common marker for MVs. However, recent studies sug-
gest the presence of annexin V-negative MVs. Indeed, it
has been reported that annexin V-negative MVs account
for more than 80% of the platelet-derived vesicles in blood
plasma [51]. This study controlled for the effect of annexin
V binding, demonstrating that it requires at least 1.25 mM
calcium for binding. They also drew attention to the fact
that phosphate-buffered saline was not suitable for annexin
V staining, as calcium forms precipitates with phosphate.
In line with these results, in our work, we have found that
saline with 2.5 mM Ca
2? results in an optimal annexin V
staining [38]. Given that not all vesicles are annexin V
positive, alternative labelings of MVs with PKH67 [81]o r
bio-maleimide [82] may also prove useful to examine
correlations between MV counts and human disorders. In
blood, the most important sources of MVs are platelets, and
most studies analyzed the alterations of levels of platelet-
derived microparticles (pMVs) under several conditions
anddiseases.Recentstudieshavesuggestedthatthemajority
of the CD41
? pMVs were derived from megakaryocytes
rather than from platelets [83]. The megakaryocyte-derived
vesicles did not carry CD62P, but displayed full-length ﬁl-
amin A [83]. Further studies are required to clarify the
potential diagnostic and/or prognostic values of megak-
aryocyte-derived vesicles.
An additional problem is that any structure that shares
size and consequently scattering properties with MVs,
would also appear during FC within the gate used for MP
detection. We have demonstrated recently that insoluble
immune complexes may also give signals at FC, and thus
interfere with MV measurements. When all events are
considered as MVs within the MV gate, the presence of
immune complexes in RA synovial ﬂuid may overestimate
true vesicle counts [38]. Furthermore, we showed that,
when using indirect labeling, primary and secondary anti-
bodies formed immune complexes detectable within the
MV gate as ﬂuorescent events. Importantly, not only
immune complexes but alo streptavidine-biotinylated
antibodies and antibody aggregates may form supramo-
lecular protein complexes detectable within the MV gate.
The MV and protein complex-related events may be easily
discriminated by using low concentrations of detergents
enough to lyse MVs but insufﬁcient to disassemble
immune complexes and protein aggregates [38]. The
optimal concentration of the detergent (i.e., Triton X-100),
which discriminates vesicles from protein aggregates,
should be titrated for individual settings. Furthermore, it is
recommended to use only direct immunolabelling when
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mation. However, it is important to note that some vesicle
subpopulations may be particularly resistant to such lysis;
therefore, detergent lysis may not be considered as a
guarantee to lyse all types of membrane vesicles.
To conclude, FC is a powerful technique to analyze
membrane vesicles; however, as it has serious limitations,
all FC data on membrane vesicles should be interpreted
cautiously.
Potential contamination of membrane vesicle preparations
To study the effect of secreted membrane vesicles, it is of
high importance to examine isolated vesicle populations.
Beyond membrane vesicles, biological ﬂuids may also
contain high amounts of different types of particles (lipo-
proteins, viruses) or molecules with the tendency to form
aggregates or complexes. These complexes or particles not
only disturb the detection of membrane vesicles (as dis-
cussed in the previous section), but may also co-sediment
with various membrane vesicle populations. Roughly,
exosomes overlap in size with viruses and lipoproteins,
while MVs overlap the size range of bacteria (Fig. 3). In
the case of viruses, even sucrose gradients are inefﬁcient at
separating them from exosomes [78]. This problem may be
solved using iodixanol gradients, which have been shown
to separate exosomes from retroviruses [78]. Furthermore,
proteins may also contaminate isolated exosome prepara-
tions, as suggested by Rood et al. [84]. The authors showed
that, after ultracentrifugation or nanomembrane ultraﬁltra-
tion, the pellet contained very high amounts of
contaminating proteins from patients with nephrotic syn-
drome. Our group has also shown that preparations of MVs
isolated by differential centrifugation may be contaminated
by protein complexes, especially by insoluble immune
complexes [38]. We have demonstrated shared size and
sedimentation properties of immune complexes and MVs,
which may result in contamination of conventionally
isolated MV preparations.
Membrane vesicle populations may also be contami-
nated by microsomal fractions or organelles released from
necrotic cells (in particular in tumors); thus, corresponding
controls (endoplasmic reticulum-related molecules) should
be run in studies of isolated membrane vesicles.
In conclusion, exosomes represent the best characterized
population within the family of membrane vesicles. How-
ever, the isolation, sizing and measurement of MVs and
apoptotic bodies remains elusive. There have been signif-
icant advances in FC detection and standard isolation of
MVs, but pre-analytical factors still remain a challenge.
Additionally, quality control of EV preparations is essential
prior to functional assays, if describing a speciﬁc function
of exosomes or MVs.
Conceptual and theoretical issues related to membrane
vesicles
Themostchallenging conceptualissueinthe ﬁeld isthe lack
of standard terminology and methodology which hampers
efﬁcient information ﬂow. International meetings may offer
unique opportunities to establish such a consensus.
Current studies test isolated populations of membrane
vesicles in vitro. Thus, the effect of a single vesicle type
ratherthanacomplexvesicularpatternisassessed(albeitthe
latter probably reﬂects in vivo situations more realistically).
Combinatorial signaling induced by different vesicles (such
as exosomes and MVs) or vesicles in combination with
soluble molecules (such as cytokines), has not yet been
investigated. Thus, synergistic or additive effects cannot be
estimated.Sizedistributionofvesiclesreleased by apoptotic
cells has not yet been systematically explored. Therefore,
exclusion of apoptotic bodies ([1,000 nm) from studies on
membrane vesicles may lead to loss of relevant information
with respect to EVs. Furthermore, lack of information on
local concentrations and half lives of membrane vesicles in
tissuespreventsdrawingconclusionsfrominvitrofunctional
assays with secreted membrane vesicles.
Finally, the striking structural and functional similarities
between exosomes and viruses raise interesting questions.
As mentioned earlier, size distributions of exosomes and
viruses show a substantial overlap (Fig. 3). Furthermore,
both exosomes and many viruses are essentially lipid and
protein shells enclosing nucleic acids, and their nucleic acid
content is released into the cytosol of the cell. As with
viruses, transcription of exosomal RNA has been convinc-
ingly shown in cells after uptake of the vesicles [19]. Thus,
the description of exosomes may well ﬁt viruses, and the
borderline of these two structures might be somewhat blur-
red. A clear difference is the ability of viruses to replicate
inside the infected cells. The intriguing possibility is raised
that membrane vesicles (such as exosomes) and viruses may
havephylogeniclinks.HIV-1andexosomeswerereportedto
share a common glycome arguing for a common origin [85].
It may be hypothesized that certain cell-derived vesicles
(carrying enzymes and nucleic acids) might have proven
evolutionarily successful to replicate inside cells following
their uptake. From this aspect, enveloped viruses such as
HIV or inﬂuenza virus might be of particular interest, since
during their release from cells these viruses acquire an
envelope, which is a modiﬁed piece of the host’s plasma- or
internal membrane. It remains an exciting question as to
whether viruses like HIV hijack the exosomal dissemination
system as suggested [20], a concept that has been refuted in
the recent past [86], or they might have taken advantage of
cellular vesiculation early during their evolution. Further-
more, it was shown that exosomes from cytomegalovirus-
infected (CMV) HUVEC cells contain CMV proteins and
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noma cells with latent EBV infection, also contain viral
proteins as well as virus-speciﬁc miRNAs [88].
In the next section, we make an attempt to brieﬂy
overview the experimental settings that may serve to
investigate the functions of EVs.
Experimental systems to study membrane vesicles
In vitro modulation of vesicle formation may be achieved
by various compounds. The family of potentially targeted
pathways and proteins that participate in the release of
exosomes and MVs are numerous, and their number is
continuously expanding.
Stimulation of certain cell-membrane receptors leads to
increased secretion of membrane vesicles. These include
P2X(7)R [44, 89, 90] and thrombin receptor [91] or GPVI
collagen receptor on platelets [45]. P2X(7)R can be stim-
ulated by ATP or the antimicrobial peptide LL-37 [92], or
inhibited by rotterlin [93] and various protein tyrosine
kinase antagonists [94]. Resting B cells, T cells, mast cells
and reticulocytes can also secrete vesicles after activation
of their cell surface receptors [2]. Exosome secretion may
be induced by activation of the T cell receptor or reduced
by LPS in dendritic cells [95, 96].
Downstream pathways of cell surface receptors may
also be modulated to modify vesicle secretion. Calcium
ionophores stimulate vesicle release by elevating intracel-
lular calcium levels in various cells [97, 98]. Calpeptin, an
inhibitor of calmodulin, decreases MV shedding in plate-
lets [99]. Exosome release may also be blocked in
melanoma cells by the pretreatment of proton-pump
inhibitors, which reduce the acidic milieu [100]. In tumor
cells, the GTP binding protein ARF6-GTP activates phos-
pholipase D which recruits extracellular signal-regulated
kinase (ERK) to the plasma membrane, where ERK acti-
vates myosin light-chain kinase (MLCK). The latter
molecule is needed for membrane vesicle secretion; thus,
inhibition of ARF6 activation blocks MV shedding [101].
The ceramid pathway can be modulated by inhibition of the
synthesizing enzyme, neutral sphingomyelinase [102].
Finally, effector molecules that take part in membrane
vesicle formation may also be inhibited. The compound
R5421 inhibits scramblase, and reduces MV shedding in
reticulocytes [103], while inhibition of the known sheddase,
ADAM17, also reduces MV production in platelets [104].
Of note, most proteins involved in vesicle trafﬁcking
also have other vital functions, thus blocking them may
have detrimental consequences for cells. Strikingly,
blocking of Rab27a or Rab27b impairs exosome secretion,
without affecting conventional protein secretion [105].
In vivo models suitable for studying vesicle production
are almost completely lacking. Scott syndrome, a rare
bleeding disorder, is the only known human disease caused
by inheritable deﬁciency of MV production of human
platelets as a result of impaired phosphatidyl-serine trans-
membrane migration and Ca
2?-induced phospholipid
scrambling [106]. This disease has also been described in a
pedigree of German sheepdogs [107], and the gene
responsible was linked to canine chromosome 27 [108].
This dog disease could serve as an in vivo animal model to
study impaired platelet vesicle secretion.
Human gene polymorphisms may affect membrane
vesicle secretion. IL-1b has been shown to be secreted via
membrane vesicles after activation of the P2X(7) receptor
and Toll-like receptors in monocytes and macrophages [44,
109]. The gain of function A348T polymorphism of
P2X(7)R was shown to induce increased IL-1b secretion
after LPS priming in monocytes [110], although in this case
the route of secretion was not analyzed. However, the
G496A loss of function mutation of the same gene was
reported to decrease both secretion of IL-1b and shedding
of L-selectin [111]. Polymorphisms of other genes,
encoding for proteins that take part in MV formation and
secretion, offer possibilities for studying membrane vesi-
cles. Thus, polymorphisms and mutations of genes that
inﬂuence EV formation may serve as valuable tools to
study vesicle formation processes.
On the other hand, membrane vesicle research may also
beneﬁt from lessons of in vivo experimental models of
impaired vesicle secretion. Various knock-out mice may
serve as attractive mammalian candidates to study deﬁ-
ciency of proteins that participate in membrane vesicle
formation. For instance, leukocytes of P2X(7)R-deﬁcient
mice are characterized by reduced shedding of L-selectin,
and decreased secretion of IL-1b in response to LPS and
ATP [112]. Tumor suppressor-activated pathway 6
(TSAP6)-deﬁcient mice show microcytic anemia, with
abnormal reticulocyte maturation and deﬁcient transferrin
receptor downregulation, features which are all dependent
on exosome secretion. Exosome production is also
impaired in TSAP6 null cells [113].
Mice, genetically deﬁcient in the clearance of membrane
vesicles (e.g., phosphatidyl-serine knockout mice [114]o r
T cell immunoglobulin and mucin domain-containing
protein 4 (TIM4)-deﬁcient mice [115]) represent another
type of in vivo experimental system to study membrane
vesicles. The signiﬁcance of such an in vivo system is
supported by the observation that TIM4-deﬁcient mice
exhibit autoimmunity and T and B cell hyperactivity [115].
Recently, Tyro3/Axl/Mer (TAM) signaling has been
implicated in the ‘homeostatic phagocytosis’ of apoptotic
cells and membranes [116]. Similarly to TIM4-deﬁcient
mice, TAM-deﬁcient mice develop autoimmunity [117].
The human autoimmune disease systemic lupus erythe-
matosus (SLE) may offer another in vivo system to
Membrane vesicles, current state-of-the-art 2675
123investigate membrane vesicles, as SLE is characterized by
an impaired clearance of apoptotic bodies [118–123].
Comprehensive meta-analysis of proteomic studies
on different types of membrane vesicles
In contrast to sporadic publications on membrane vesicle
lipidomics [124–127], metabolomics [128] or glycomics
[85], information regarding the protein composition of EVs
may be readily extracted from numerous published pro-
teomic studies as well as from a database [129]. In order to
obtain a reliable and representative set of proteins identi-
ﬁed in exosomes, we ﬁltered the ExoCarta database [129]
for proteomic studies, and selected only data from sources
in which human exosomes were puriﬁed by density gra-
dient ultracentrifugation [126, 129–133]. Unlike in the case
of exosomes, there is no comprehensive database for pro-
teomic data regarding MVs. While the diversity of tissue
types analyzed by exosome studies makes the obtained
dataset representative for these structures, at present there
is a clear overrepresentation of data concerning platelet-
derived MVs in the literature. In the MV dataset, we
included data from proteomic studies on human platelet or
plasma-derived MVs, in which protein data were supplied
in a clearly accessible format [128, 134–136]. Subcellular
localization of proteins can be readily analyzed using the
annotations of the SwissProt/UniProt database [137, 138].
Although the proteomic studies from which the protein
datasets were extracted also investigated the subcellular
localization of molecules, the different methods of vesicle
isolation and analysis interfered with the comparison of the
results from individual studies.
One may anticipate that the subcellular localization of a
protein in an intact cell is in concordance with the possible
localization in a membrane vesicle. Since both exosomes
and MVs are considered to consist of cytoplasm enclosed
by a lipid bilayer, it was interesting to ﬁnd a notable por-
tion of nuclear proteins in both vesicle populations (Fig. 5).
Given that platelets have no nuclei, the presence of nuclear
proteins in MVs isolated from blood plasma supports the
recent observation that circulating MVs are of megak-
aryocyte rather than platelet origin [83]. Nuclear proteins
may originate from the preparation methods, as centrifu-
gation may also pellet apoptotic or necrotic materials
(apoptotic bodies, nuclear fragments or nucleosomal
complexes) together with MVs. Dean et al. demonstrated
that nuclear proteins are not evenly distributed in all size
fractions of platelet-derived MVs [136]. Of note, cytosolic
proteins, known to undergo nuclear translocation, may
have also increased the frequency of nuclear proteins, as
we included proteins in all their possible subcellular
localizations (according to SwissProt-UniProt annotations)
when generating Fig. 5. In contrast to the unexpectedly
high ratio of nuclear proteins found in MVs, exosomes
contained only limited amounts of nuclear proteins.
Membrane-associated proteins, on the other hand, consti-
tuted the major fraction of exosomal proteins.
One of the possible functions of membrane vesicles is
contributing to non-classical leaderless secretion of pro-
teins such as IL-1b [139]. Taking advantage of the recently
available prediction tools to determine which proteins are
likely to undergo leaderless secretion [140], we used the
SecretomeP 2.0 software from CBS [141] on a dataset
previously ﬁltered for cytoplasmic proteins. All membrane
proteins are likely to contain a signal sequence and thus
avoid leaderless secretion. Using this prediction tool, we
analyzed data obtained in six studies on exosomes and four
studies on MVs. From all cytoplasmic proteins in each
dataset, around 30% were predicted to be secreted non-
classically. The remaining molecules (such as cytoskeletal
proteins) could contribute to a protective shell stabilizing
vesicular structure, and may carry targeting information.
Fig. 5 Subcellular localization of proteins identiﬁed in exosomes
(a) and MVs (b) The published proteomic studies are indicated by the
name of the ﬁrst author
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lating immune responses, it is critical to achieve the right
concentration at the right site. Although it is degraded
rapidly in human plasma (its half-life is 6 min [142]), it
might be preserved for a longer time inside vesicles, thus
enabling it to act systematically or locally, but distant
from the site of its production. For IL-1b, the majority of
leaderless secretion has been reported to occur by exo-
somes [143].
The fact that molecules, predicted to undergo leaderless
secretion, were not detected in substantial amounts in
vesicles might either suggest an alternative route for non-
classical secretion (other than by secretion of membrane
vesicles), or may result from limitations of current pre-
diction tools. Indeed, transporters have also been suggested
to be involved in leaderless protein secretion [144], rep-
resenting a minor alternative to release by exosomes.
When exosome- and MV-associated proteins were ana-
lyzed for major biological functions by Ingenuity Pathway
Analysis (IPA; Ingenuity Systems, Mountain View, CA,
USA), in the case of both vesicle populations, cellular
movement, cell-to-cell signaling, tissue development and
cancer were among the top associated biological functions.
The function ‘‘cell death’’ was associated more with MVs
than with exosomes (in agreement with the observation that
release of MVs is induced during apoptosis). In contrast to
exosomes, MV proteins were found to be associated with
inﬂammation, and this function was ranked 10th in the case
of MVs, whereas it was ranked only 30th for exosomes
(data not shown).
According to the IPA software, many of the key mole-
cules implicated in viral entry into cells are also detectable
in exosomes (Fig. 6a). These molecules expressed by both
exosomes and cells bind a variety of viruses, like SV40,
Filo-, Coxsackie’s-, Echo-, and Arena viruses and even
HIV1. The presence of numerous virus binding proteins in
exosomes is in line with the fact that virus entry via
endocytic pathways is a well-known attribute to exosomes,
reviewed recently by Izquierdo-Useros et al. [145]. Out of
all biological pathways in the IPA knowledge base, the
most adequate ﬁt of MV proteins appeared to be integrin-
mediated signal transduction (Fig. 6b). The integrin path-
way is involved in regulating cell shape and motility in
response to changes in the extracellular environment. MV
proteins implicated in this pathway include actin, talin and
vinculin, molecules involved in regulating cell shape and
cellular movement. The signiﬁcance of the abundant
virus binding proteins in exosomes and MV molecules
involved in integrin signaling remains to be elucidated
experimentally.
Top canonical functions, identiﬁed by IPA software in
association with exosomes and MVs, are included in
Table 2. While many of the identiﬁed pathways revealed
known features of membrane vesicles, germ cell–Sertoli
cell signaling in exosomes, however, seems to represent an
unexpected pathway. During spermatogenesis, actin-based
adherens junctions at the interface of Sertoli and germ cells
undergo extensive restructuring. This facilitates germ cell
movement across the epithelium. The dynamics of these
junctions are regulated by the integrin/RhoB/ROCK/LIMK
pathway [146]. The clear nature of this pathway in the case
of exosomes remains to be established, and at this point we
cannot exclude the possibility that it may be an issue
related to the in silico analysis rather than a real biological
process existing in exosomes.
Medical implications of the extracellular vesicles
In the present review, we have described the diverse con-
stituents of the extracellular vesicular compartment. The
ubiquitous formation of membrane vesicles allows the
clinician to exploit their diagnostic value in various dis-
eases (Table 3) and conditions. Exosomes are smaller, but
can serve as tumor markers. MVs are investigated thor-
oughly as diagnostic tools due to their larger size and
accessibility in several biological ﬂuids. Most groups have
focused on blood-derived MVs. Here, we discuss the most
widely studied endothelial- and platelet-derived MVs as
well as some recent advances of tumor vesicle-based
diagnostic studies.
Endothelial MVs (eMVs)
Endothelial cells can release exosomes, endothelial MVs
(in the literature often also referred to as EMPs) and
apoptotic bodies [24]. eMVs are formed in vitro after
stimulation with LPS, reactive oxygen species and various
cytokines [24]. They are detectable in human blood plasma
by FC using endothelial cell-speciﬁc markers (CD54,
CD62E, CD62P, CD31, CD106, CD105, CD144, CD146)
[24]. Despite the limitations of FC, eMVs are considered to
be markers of inﬂammation, endothelial injury and endo-
thelial dysfunction [147–149]. As endothelial dysfunction
is a well-known predictor of future cardiovascular diseases,
eMVs could be used as biomarkers of vascular health.
eMVs are elevated in the blood plasma of patients with
acute and chronic vascular disorders, including acute
coronary syndrome [150], severe hypertension [151], end-
stage renal failure [149] and pulmonary arterial hyper-
tension [152] (for a review, see [153]) (Table 3). eMVs
have a controversial role in the pathogenesis of vascular
diseases [18]: eMVs may contribute to vascular injury and
they are capable of inducing endothelial cell activation,
impairing vasorelaxation [154], and promoting arterial
stiffness. Furthermore, phosphatidyl-serine and/or tissue
factor positive eMVs promote coagulation and
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eMVs may induce angiogenesis or promote endothelial
cell survival [24].
Platelet MVs (pMVs)(Fig. 4)
The majority of circulating MVs in the blood plasma are
derived from platelets during platelet activation or, as
suggested recently, from megakaryocytes [83]. In vitro,
pMVs are formed during stimulation of platelets with
collagen, thrombin or ADP. Shear stress and agitation also
induces pMV formation. pMVs are easily detected by FC
using CD41, CD42, CD61, and CD62 markers. Similarly to
eMVs in endothelial activation, pMVs are considered as
platelet activation markers. Therefore, numerous diseases
are characterized by elevated levels of pMVs (Table 3),
including cardiovascular diseases, autoimmune diseases
[62] and type II diabetes. pMVs may also expose phos-
phatidyl-serine and tissue factor, and they may also
contribute to the pathogenesis of vascular diseases due to
Fig. 6 Ingenuity Pathway Analysis (IPA) of data from meta-analyses
of published proteomic studies on exosomes and microvesicles.
a Molecules implicated in viral entry by caveola- and clathrin-
mediated endocytosis as well as by macropinocytosis. Shaded
symbols represent molecules identiﬁed in exosomes. As shown,
several exosomal proteins are present in the IPA knowledgebase as
molecules that facilitate the entry of different viruses. b Molecules
involved in integrin signaling. Shaded symbols represent published
microvesicle-associated proteins as key participants of integrin
signaling
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123Table 2 Top vesicle-associated canonical pathways identiﬁed by Ingenuity Pathway Analysis
MPs/MVs Exosome
Canonical pathway P value Ratio Canonical pathway P value Ratio
Actin cytoskeleton signaling 6.05E-14 38/238 Germ cell-Sertoli cell junction signaling 1.20E-23 45/168
Integrin signaling 5.18E-11 32/205 Integrin signaling 1.65E-21 47/205
RhoA signaling 4.53E-09 21/110 Caveolar mediated endocytosis signaling 2.92E-21 30/85
Caveolar mediated endocytosis signaling 1.12E-08 17/85 Virus entry via endocytic pathways 1.58E-20 32/100
Acute phase response signaling 2.21E-08 26/183 Ephrin receptor signaling 2.42E-20 43/199
The P value is calculated using the right-tailed Fisher Exact Test. It is a measure of the likelihood that the association between a set of analyzed
molecules and a given pathway is due to random chance. The ‘‘ratio’’ expresses the fraction of molecules ﬁtting a given pathway within an
analyzed dataset and the total number of molecules known to be associated with that pathway in Ingenuity’s knowledge base
Table 3 Diagnostic or prognostic alterations of the extracellular vesicles
Disorders Type of vesicles Alterations of the extracellular
vesicular compartment
References
Autoimmune diseases
Systemic lupus erythematosus pMVs and eMVs Elevated levels of pMVs and eMVs in blood plasma [52, 168]
Anti-phospholipid syndrome pMVs and eMVs Elevated levels of eMVs and pMVs in blood plasma [169, 170]
Rheumatoid arthritis pMVs Elevated levels of pMVs in blood plasma, elevated levels of annexin
V
? MVs and pMVs in synovial ﬂuid
[38, 45, 52,
171,
172]
Systemic sclerosis pMVs, eMVs and lMVs Elevated levels of pMVs, eMVs and lMVs in blood plasma [173, 174]
Vasculitis pMVs, eMVs and lMVs Increased number of pMVs and lMVs in acute vasculitis and increased
numer of pMVs and eMVs in systemic vasculitis
[175–177]
Type 1 diabetes mellitus pMVs, eMVs Increased number of eMVs and pMVs, increased total MV
procoagulant activity
[178]
Multiple sclerosis pMVs, eMVs Elevated levels of pMVs and elevated levels of eMVs during
exacerbation
[179, 180]
Cardiovascular diseases
Acute coronary syndrome pMVs, eMVs High levels of procoagulant eMVs and pMVs are present in the
circulating blood of patients. High eMV level was associated with
high-risk angiographic lesions in patients with acute coronary
syndromes. Levels of eMVs may predict future cardiovascular
events in patients at high risk for congestive heart failure
[150, 181–
185]
Hypertension eMVs, pMVs Levels of eMVs and pMVs correlate with blood pressure.
Hypertensive patients with microalbuminuria have higher levels of
eMVs compared to hypertensive patients without microalbuminuria
[151, 186]
Pulmonary hypertension pMVs, eMVs, lMVs eMVs predict severity of pulmonary hypertension. Elevated levels of
pMVs, eMVs and lMVs predict vascular inﬂammation and
hypercoagulability
[152, 187,
188]
Congestive heart failure eMVs Apoptotic eMVs are elevated in patients with congestive heart failure.
Furthermore, the levels of eMVs correlate with NYHA functional
classes. Patients undergoing heart transplantation due to heart
failure show altered phenotypes of eMVs
[189–191]
Deep vein thrombosis (DVT)
and venous thromboembolism
eMVs, pMVs pMVs and eMVs are elevated in patients with DVT. Total MV count
may serve as novel markers for DVT. Circulating MVs and pMVs
are elevated in patients with acute pulmonary embolism
[192–194]
Buerger’s disease pMVs pMVs are markers of exacerbation [195]
Atherosclerosis lMVs, pMVs CD11a positive lMVs predict subclinical atherosclerosis. pMVs are
elevated in individuals with carotis atherosclerosis
[196, 197]
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123Table 3 continued
Disorders Type of vesicles Alterations of the extracellular
vesicular compartment
References
Cerebrovascular disorders pMVs, eMVs, lMVs
and erythrocyte MVs
pMVs are elevated in transient ischaemic attacks, lacunar infarcts and
multiinfarct dementias. pMVs, eMVs, lMVs and erythrocyte MVs
are elevated in patients with subarachnoid hemorrhage and are
markers of vasospasm. Circulating eMV phenotypic proﬁles reﬂect
distinct phenotypes of cerebrovascular disease
[198–202]
Hematologic diseases
Paroxysmal nocturnal
haemoglobinuria
eMVs Elevated levels of eMVs [203]
Sickle cell disease eMVs, pMVs,
erythrocyte-MVs,
Elevated levels of total MVs, eMVs, pMVs and erythrocyte MVs,
particularly in sickle cell crisis
[204]
Immune thrombocytopenic
purpura (ITP)
pMVs pMVs are elevated in patients with acute ITP and decreased in chronic
ITP
[205]
Thrombotic
thrombocytopenic purpura
eMVs Elevated levels of eMVs [206]
Cancer
Lung adenocarcinoma Exosomes Elevated level of exosomes and miRNA in blood plasma of patients. [163]
Glioblastoma Tumor-derived
exosomes
Tumor-speciﬁc EGFRvIII was detected in serum exosomes from
patients
[159]
Ovarian cancer Tumor-derived
exosomes
Exosomal miRNA from ovarian cancer patients exhibited distinct
proﬁles compared to patients with benign disease
[161]
Prostate cancer Tumor-derived
exosomes in blood
and urine
Detection of tumor-speciﬁc exosomes in blood could be used as a
screening test. Urinary exosomes contain biomarkers for prostate
cancer
[164, 207,
208]
Colorectal cancer Tumor-derived
exosomes
Detection of tumor-speciﬁc exosomes in blood could be used as a
screening test
[165]
Gastric cancer pMVs pMVs are markedly increased in patients with stage IV disease and
might be useful for identifying metastatic gastric patients.
[209]
Melanoma Exosomes Elevated CD63 and caveolin 1 on exosomes [210]
Oral cancer Exosomes Sera of patients with active oral squamous cell carcinoma contain
FasL
? exososmes
[211]
Cancer associated
thrombosis
TF
? MVs TF
? MVs are elevated in patients with colorectal carcinoma, multiple
myeloma, breast and pancreatic adenocarcinoma
[212–214]
Other diseases
Alzheimer’s disease pMVs pMVs carry amyloid b on their surface [215]
Type 2 diabetes mellitus pMVs, lMVs Elevated levels of pMVs, especially in patients with clinically
apparent atherosclerosis, elevated percentage of TF
? MVs. Patients
with nephropathy have higher number of monocyte-MVs
[216–219]
Metabolic syndrome MVs exposing TF,
eMVs
The level of TF exposing MVs correlate with the components of
metabolic syndrome. Pioglitazon has been shown to reduce eMV
levels in patients with metabolic syndrome
[218, 220,
221]
End-stage renal disease eMVs, PMVs Total annexin V
? MVs, pMVs, eMVs are elevated in patients with
end-stage renal disease and patients with hemodialysis. eMVs
predict vascular dysfunction and represent a marker of endothelial
dysfunction
[149, 222]
Obstructive sleep apnoe pMVs, lMVs, eMVs Total annexin V
? MVs, pMVs, lMVs and eMVs are elevated in
patients
[223, 224]
Preeclampsia eMVs, lMVs, pMVs,
synctiotrophoblast
MVs.
Elevated levels of eMVs, syncytiotrophoblast MVs pMVs and lMVs [225–230]
Sepsis pMVs, eMVs,
granulocyte MVs
pMVs and eMVs are elevated in septic shock, but their elevation
predicts favorable outcomes. Patients with meningococcal sepsis
have elevated numbers of pMVs and granulocyte-derived MVs
[231–233]
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only blood plasma but also synovial ﬂuid from RA patients
contain high amounts of pMVs [45] and activate synovial
ﬁbroblasts via their IL-1 content. In accordance with these
results, numerous publications have demonstrated the ele-
vated levels of pMVs in the blood plasma of patients with
various rheumatic diseases (Table 3)[ 62]. pMVs are
characterized by a highly adhesive surface and may bind to
endothelial cells, leukocytes and matrix molecules [155].
Furthermore, adherent MVs may also transfer GPIIb/IIIa to
cells, including neutrophils [156], leading to cell activa-
tion. In summary, pMVs possibly represent novel players
in the network of inﬂammation and autoimmunity.
Tumor-derived membrane vesicles
Tumors are characterized by secretion of various forms of
membrane vesicles constitutively. These comprise exo-
somes [157], MVs [158] and apoptotic bodies (as a result
of increased apoptosis in tumors). Released membrane
vesicles contain tumor-speciﬁc antigens on their surface,
e.g., Her2/Neu mesothelin, MelanA/Mart-1, CEA, HER-2,
and EGFRvIII [19, 157, 159]. Furthermore, membrane
vesicles from cancer cells contain RNA. Several reports
indicate that miRNA-based identiﬁcation of cancer leads to
a reliable characterization of the origin and development of
tumors [160, 161]. miRNAs, circulating in serum, plasma,
saliva and breast milk, are resistant to degradation [160],
and therefore it was suggested that miRNAs are protected
by lipid or lipoprotein complexes [162]. As certain miR-
NAs are characteristic for tumors, their presence within
tumor-derived exosomes and MVs may serve as novel
biomarkers of cancer. The exosomal miRNA levels or
patterns showed correlation with lung adenocarcinoma
[163], glioblastoma [159] and ovarian cancer [161].
Recently, a EV-based diagnostic platform has been
developed for the diagnosis of prostate cancer [164]. In this
study, prostate tumor-speciﬁc vesicles in blood plasma
have been identiﬁed using simultaneous detection of
prostate-, tumor- and exosome-speciﬁc markers. Using this
‘‘biosignature’’ of prostate cancer EVs, diagnostic speci-
ﬁcity and sensitivity of 83 and 90%, respectively, have
been reached. This group also analyzed EVs from colo-
rectal cancer patients in blood plasma, and diagnostic
sensitivity and speciﬁcity of 85 and 85%, respectively,
have been reported [165]. These data suggest that tumor-
derived membrane vesicles could open a new era in cancer
screening and diagnostics in the near future. The technol-
ogy used in these studies, however, does not speciﬁcally
purify exosomes or MVs [166], yet appears to be diag-
nostically useful. Thus, careful isolation of given EV
subpopulations in a clinical monitoring assay may be less
important than previously thought.
Importantly, EVs (in particular exosomes) have been
recently suggested to serve as novel therapeutic agents
against cancer. Ongoing Phase I and Phase II trials and
therapeutic strategies have been reviewed recently by
Chaput and Thery [22]. Moreover, EVs may serve as novel
promising vectors for future gene therapy [167].
Conclusions
Based on recent convergent data, we propose that there
exists a previously poorly recognized, complex and
dynamic extracellular vesicular compartment. Depending
on the functional state of cells in the tissues, the compo-
sition of this compartment may change spatially and
temporarily. The plasticity of the compartment may enable
adaptation to altered conditions, and its evolutionarily
conserved nature suggests efﬁcient and vital biological
functions of this compartment. At present, we are still far
from fully appreciating the biological signiﬁcance of EVs.
Collectively, constituents of this compartment represent
large membrane surface areas, and their amount in the
extracellular space might be best appraised on the basis of
their membrane lipid content or lipid/protein ratio. Bio-
logical systems in which vesicles are released into large
volumes of extracellular ﬂuid, such as blood plasma or
tissue culture medium (where they are not taken up
immediately by surrounding cells), provide some clues
about the magnitude of vesicle formation and the efﬁcacy
of clearance in tissues. Their molecular composition shows
striking similarities including the shared presence of
cytoskeletal proteins, membrane lipid composition and
externalized phosphatidylserine, just to mention a few
examples. Size distribution is another area of overlap. Even
though not characterized in detail, it may be hypothesized
that uptake and removal by cells occurs by similar or
identical molecular mechanisms.
Similarly to cytokines that constitute a network of com-
munication,EVsmayalsoexerttheirfunctionsinanetwork,
which is acting in a speciﬁc context with many other
players. The long list of medical implications, affecting
different organs, justiﬁes systems biology approaches to
study EVs.
Understanding of this compartment challenges the cur-
rent paradigms concerning the mechanisms of intercellular
communication and immune regulation. It may also open
new perspectives in translational medicine both in diag-
nostics and therapy.
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